These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 15689089)

  • 1. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
    Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
    Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of varicella vaccination of healthcare workers.
    Chodick G; Ashkenazi S; Livni G; Lerman Y
    Vaccine; 2005 Oct; 23(43):5064-72. PubMed ID: 16046036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
    Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
    Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic analysis of the universal varicella vaccination program in the United States.
    Zhou F; Ortega-Sanchez IR; Guris D; Shefer A; Lieu T; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S156-64. PubMed ID: 18419391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ; de Melker HE; Stolk EA; de Wit GA; Kimman TG
    Vaccine; 2006 Sep; 24(37-39):6288-99. PubMed ID: 16790302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic value of childhood varicella vaccination in France and Germany.
    Coudeville L; Brunot A; Szucs TD; Dervaux B
    Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.
    Hammerschmidt T; Bisanz H; Wutzler P
    Vaccine; 2007 Oct; 25(42):7307-12. PubMed ID: 17881097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule.
    Scuffham P; Devlin N; Eberhart-Phillips J; Wilson-Salt R
    Soc Sci Med; 1999 Sep; 49(6):763-79. PubMed ID: 10459888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
    Bonanni P; Boccalini S; Bechini A; Banz K
    Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan.
    Tseng HF; Tan HF; Chang CK
    Southeast Asian J Trop Med Public Health; 2005 Nov; 36(6):1450-8. PubMed ID: 16610647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a routine varicella vaccination program for US children.
    Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
    JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of varicella vaccination in Spain: results from a dynamic model.
    Lenne X; Diez Domingo J; Gil A; Ridao M; Lluch JA; Dervaux B
    Vaccine; 2006 Nov; 24(47-48):6980-9. PubMed ID: 16860909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
    Knuf M; Neiss A; Wutzler P
    Klin Padiatr; 2006; 218(4):203-12. PubMed ID: 16819701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic considerations of vaccination against varicella.
    Strassels SA; Sullivan SD
    Pharmacotherapy; 1997; 17(1):133-9. PubMed ID: 9017774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of varicella vaccination programs: an update of the literature.
    Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
    Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.